2.49
-0.08 (-3.11%)
| Penutupan Terdahulu | 2.57 |
| Buka | 2.58 |
| Jumlah Dagangan | 382,268 |
| Purata Dagangan (3B) | 629,903 |
| Modal Pasaran | 182,111,088 |
| Harga / Jualan (P/S) | 1.88 |
| Harga / Buku (P/B) | 0.600 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -19.77% |
| Margin Operasi (TTM) | -61.02% |
| EPS Cair (TTM) | -0.420 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -44.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.58% |
| Nisbah Semasa (MRQ) | 12.34 |
| Aliran Tunai Operasi (OCF TTM) | 27.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 12.04 M |
| Pulangan Atas Aset (ROA TTM) | -4.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -7.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Menurun | |
| Stok | OraSure Technologies, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 3.5 |
| Purata | 1.33 |
|
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.83% |
| % Dimiliki oleh Institusi | 89.49% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| EGLINTON MANNER CARRIE | - | - | 0 | 0 |
| MCGRATH KENNETH J | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| EGLINTON MANNER CARRIE | Pegawai | 20 Mar 2026 | 32,300 | - | - | |
| MCGRATH KENNETH J | Pegawai | 20 Mar 2026 | 32,300 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 15 Jan 2026 | Pengumuman | OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital |
| 15 Jan 2026 | Pengumuman | Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors |
| 05 Jan 2026 | Pengumuman | OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |